Home›Stock Screener›Johnson Pharmacare›Intrinsic Value

Johnson Pharmacare Intrinsic Value

Johnson Pharmacare intrinsic value. Johnson Pharmacare (JOHNPHARMA) median intrinsic value is ₹0.29 from 1 valuation models (range ₹0–₹0), vs current price ₹0.44 — -34.1% downside (Trading Above Calculated Value), margin of safety -51.7%. Analyse JOHNPHARMA shareholder distribution to track promoter, FII and institutional holdings.

Market Price (CMP)
₹0.44
Primary Intrinsic Value
₹0.29
Market Cap
₹2.4 Cr
-34.1% Downside
Median Value
₹0.29
Value Range
₹0 - ₹0
Assessment
Trading Above Calculated Value
Safety Margin
-51.7%

JOHNPHARMA Valuation Methods Summary — DCF, Graham Number & P/E

Johnson Pharmacare intrinsic value across 1 models vs current price ₹0.44 — upside/downside and value range per method. Browse JOHNPHARMA balance sheet details for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
Revenue Multiple Method revenue ₹0.29 ₹0.26 - ₹0.32 -34.1% Revenue/Share: ₹0.36, P/S: 0.8x
Method Types: Earnings Asset DCF Growth Dividend Conservative

JOHNPHARMA Intrinsic Value vs Market Price — All Valuation Models

Johnson Pharmacare fair value range ₹0–₹0 vs current market price ₹0.44 across 1 valuation models. For current market price and key ratios, visit Johnson Pharmacare screener.

JOHNPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?

Johnson Pharmacare median intrinsic value ₹0.29, current price ₹0.44 — Trading Above Calculated Value by 34.1%, margin of safety -51.7%.

What is the intrinsic value of JOHNPHARMA?

Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Johnson Pharmacare (JOHNPHARMA) is ₹0.29 (median value). With the current market price of ₹0.44, this represents a -34.1% variance from our estimated fair value.

The valuation range spans from ₹0.29 to ₹0.29, indicating ₹0.29 - ₹0.29.

Is JOHNPHARMA undervalued or overvalued?

Based on our multi-method analysis, Johnson Pharmacare (JOHNPHARMA) appears to be trading above calculated value by approximately 34.1%.

JOHNPHARMA Financial Health — Key Ratios vs Industry Benchmarks

Johnson Pharmacare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Asset Turnover Ratio 0.09x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

JOHNPHARMA Cash Flow Quality — Operating & Free Cash Flow

Johnson Pharmacare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹-2 Cr ₹-2 Cr Negative Cash Flow 3/10
March 2024 ₹0 Cr ₹0 Cr Negative Cash Flow 3/10
March 2023 ₹0 Cr ₹-1 Cr Negative Cash Flow 3/10
March 2022 ₹5 Cr ₹3 Cr Positive Free Cash Flow 7/10
March 2021 ₹0 Cr ₹0 Cr Negative Cash Flow 3/10